Migliaccio Ilenia, Malorni Luca, Hart Christopher D, Guarducci Cristina, Di Leo Angelo
BMC Med. 2015 Mar 5;13:46. doi: 10.1186/s12916-015-0280-0.
The standard of care for patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancer is endocrine therapy. Endocrine agents, including aromatase inhibitors, tamoxifen, and fulvestrant, are often administered alone as first line treatment and demonstrate durable responses with limited side effects. Endocrine resistance represents a major clinical problem. In the future, poly-endocrine therapy and combination therapies with biological agents might become valuable options for the first line treatment of hormone receptor-positive advanced breast cancer. However, it will be critical to develop clinical tools that can reliably identify the subgroup of patients most likely to benefit from endocrine therapy alone, and those who might benefit from alternative approaches. Herein, we will review and discuss current issues in the endocrine treatment of postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancer.
激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌患者的标准治疗方法是内分泌治疗。内分泌药物，包括芳香化酶抑制剂、他莫昔芬和氟维司群，通常单独作为一线治疗药物使用，疗效持久且副作用有限。内分泌耐药是一个主要的临床问题。未来，多内分泌治疗以及与生物制剂的联合治疗可能会成为激素受体阳性晚期乳腺癌一线治疗的有价值选择。然而，开发能够可靠识别最有可能从单纯内分泌治疗中获益的患者亚组以及可能从替代方法中获益的患者亚组的临床工具至关重要。在此，我们将回顾和讨论绝经后激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌患者内分泌治疗的当前问题。
